Evaxion's EVX-01 Achieves 89% Target Precision With Three-Year Durability

summarizeSummary

Three-year EVX-01 data show 89% of vaccine neoantigen targets drove specific T-cell responses, and all patients held their clinical responses with no tumor progression. The data will be presented at ESMO on October 24, 2026, with an investor webinar on October 29, 2026.

check_boxKey Events · Product Development and Regulatory · EVAX

• Three-Year EVX-01 Data Show Durable Responses

  Through the third year of EVX-01 monotherapy, all patients maintained the clinical response seen at two years, with no tumor progression.

• 89% Vaccine Target Precision

  Of the personalized vaccine's neoantigen targets, 89% induced potent specific T-cell responses, up from 86% measured at the two-year follow-up.

• ESMO Poster and Webinar Scheduled

  Poster #2006P presents October 24, 2026 at ESMO 2026 in Madrid; an investor webinar with investigator Prof. Muhammad Adnan Khattak follows October 29, 2026 at 15:30 CET.

• Cash Runway Into Second Half 2027

  Evaxion maintains a cash runway extending well into the second half of 2027, according to the release, so this readout is not tied to an immediate raise.

auto_awesomeAnalysis · EVAX · Life Sciences

The real value here lies in the platform, not just the drug: 89% of the vaccine's chosen neoantigen targets triggered a tumor-specific T-cell response, up from 86% at two years, and every patient's response held through three years of monotherapy. That is the strongest validation yet of the AI-Immunology platform's target-selection ability — the actual commercial asset that partners and future vaccine programs are built on. With cash runway extending well into the second half of 2027, this is not a financing-driven story; it is clinical de-risking ahead of the ESMO poster on October 24 and the investor webinar on October 29, 2026.